most of you will remember articles that ran in the muscle mags a few months ago about a new drug that blocks the protein myostatin. This drug is perported to blow the socks off AS or HGH in its ability to grow muscles to freaky porportions.
Anyway, picked this tidbit up today on the business wire about the company involved in the creation of this new drug/treatment...
14:45 EDT Monday
MetaMorphix collects three new patents
Michele Berk Staff
The U.S. Patent and Trademark Office issued three new patents to MetaMorphix Inc., an agricultural biotech company.
The Savage, Maryland based company, which develops products to increase the nutritional value of poultry and swine, received three patents for different uses of its technology that uses the protein Myostatin.
One patent covers the use of Myostatin for the treatment of Type II diabetes. Another covers the use of Myostatin to increase muscle growth in livestock, which would increase the muscle-to-fat ratio.
A third patent was issued to the Johns Hopkins School of Medicine for the use of Myostatin to increase skeletal muscle tissue. MetaMorphix bought the exclusive rights to the Myostatin technology from Johns Hopkins.
The company sublicensed its technology to Wyeth in January 1999 for research and development of products for humans using Myostatin. MetaMorphix is receiving licensing payments and will receive royalties from any commercial products developed using Myostatin.
Anyway, picked this tidbit up today on the business wire about the company involved in the creation of this new drug/treatment...
14:45 EDT Monday
MetaMorphix collects three new patents
Michele Berk Staff
The U.S. Patent and Trademark Office issued three new patents to MetaMorphix Inc., an agricultural biotech company.
The Savage, Maryland based company, which develops products to increase the nutritional value of poultry and swine, received three patents for different uses of its technology that uses the protein Myostatin.
One patent covers the use of Myostatin for the treatment of Type II diabetes. Another covers the use of Myostatin to increase muscle growth in livestock, which would increase the muscle-to-fat ratio.
A third patent was issued to the Johns Hopkins School of Medicine for the use of Myostatin to increase skeletal muscle tissue. MetaMorphix bought the exclusive rights to the Myostatin technology from Johns Hopkins.
The company sublicensed its technology to Wyeth in January 1999 for research and development of products for humans using Myostatin. MetaMorphix is receiving licensing payments and will receive royalties from any commercial products developed using Myostatin.

Please Scroll Down to See Forums Below 










